For all that we have been through as Admedus Shareholders it can be easy to lose sight of all the progress we have made in the last 12 months in 2017.
I was going to hold off on this until the end of the year in case we got another announcement but it can always be edited. Perhaps some of you would like to speculate what the next three announcements might be and in what order for a bit of fun.
So here is a summary of all of the news flow we have had in CY (our new FY) 2017. It really was a transformational year for Admedus and I think 2018 will demonstrate that.
Onwards and upwards as we power towards 2020 and beyond.
* Approval for CardioCel in Saudi Arabia
* John Seaburg announced as Chairman
* Wayne Paterson announced as CEO
* CardioCel 3D FDA approval
* HSV 2 results
* Appointed David Saint Dennis as COO
* Exclusive supply agreement with 4C Medical.
* TAVR IP application lodged
* Capital sorted and CR raise fears put to bed with loans from PFG
* Note to file for new 3D product in Peripheral Vascular repair.
* Conclusion of 3D evaluation period and Feb 1st 2018 announced as the launch date.
* Regulatory approval to launch CardioCel in India.
And coming soon...........
2017 - A year in review.
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.31 |
Change
-0.240(1.29%) |
Mkt cap ! $351.9M | |||
| Open | High | Low | Value | Volume |
| $18.80 | $19.15 | $18.20 | $159.7K | 8.611K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 73 | $18.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.33 | 90 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |